MAIA Debt To Assets from 2010 to 2024

MAIA Stock  USD 2.00  0.01  0.50%   
MAIA Biotechnology's Debt To Assets are increasing over the years with slightly volatile fluctuation. Overall, Debt To Assets are expected to go to 0.59 this year. From 2010 to 2024 MAIA Biotechnology Debt To Assets quarterly data regression line had arithmetic mean of  0.21 and r-squared of  0.66. View All Fundamentals
 
Debt To Assets  
First Reported
2010-12-31
Previous Quarter
0.56
Current Value
0.59
Quarterly Volatility
0.28459128
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MAIA Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MAIA Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9, Interest Expense of 6.5 K or Selling General Administrative of 6.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 34.12. MAIA financial statements analysis is a perfect complement when working with MAIA Biotechnology Valuation or Volatility modules.
  
Check out the analysis of MAIA Biotechnology Correlation against competitors.
For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.

Latest MAIA Biotechnology's Debt To Assets Growth Pattern

Below is the plot of the Debt To Assets of MAIA Biotechnology over the last few years. It is MAIA Biotechnology's Debt To Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MAIA Biotechnology's overall financial position and show how it may be relating to other accounts over time.
Debt To Assets10 Years Trend
Slightly volatile
   Debt To Assets   
       Timeline  

MAIA Debt To Assets Regression Statistics

Arithmetic Mean0.21
Geometric Mean0.06
Coefficient Of Variation132.72
Mean Deviation0.26
Median0.02
Standard Deviation0.28
Sample Variance0.08
Range0.601
R-Value0.81
Mean Square Error0.03
R-Squared0.66
Significance0.0002
Slope0.05
Total Sum of Squares1.13

MAIA Debt To Assets History

2024 0.59
2023 0.56
2020 0.62

About MAIA Biotechnology Financial Statements

MAIA Biotechnology stakeholders use historical fundamental indicators, such as MAIA Biotechnology's Debt To Assets, to determine how well the company is positioned to perform in the future. Although MAIA Biotechnology investors may analyze each financial statement separately, they are all interrelated. For example, changes in MAIA Biotechnology's assets and liabilities are reflected in the revenues and expenses on MAIA Biotechnology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in MAIA Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Assets 0.56  0.59 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether MAIA Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MAIA Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maia Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maia Biotechnology Stock:
Check out the analysis of MAIA Biotechnology Correlation against competitors.
For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.34)
Return On Assets
(1.07)
Return On Equity
(5.60)
The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MAIA Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.